Carboplatin
Pancreatic Neuroendocrine Carcinoma
ECOG-ACRIN Cancer Research GroupSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Pancreatic Neuroendocrine Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Temsirolimus University of Southern California | Phase 2 | B |
Everolimus Emory University | Phase 2 | B |
Regorafenib University of Southern California | Phase 2 | B |
Oxodotreotide Alliance for Clinical Trials in Oncology | Phase 2 | B |
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
View all 27 →
Same molecule, other indications
Carboplatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →